SENTHORIS at Global Health Exhibition 2025 — Where AI Meets Human Health
Riyadh Exhibition & Convention Centre | Booth 27 |
27–30 October 2025
Imagine: health assessed in 10 seconds - through the eyes. No samples. No pain. No delay.
SENTHORIS is an AI/ML-powered digital health platform redefining how the world detects an early neuro-metabolic risks, psychoactive effects and other risks through the pupil dynamic response.
Clinically grounded and validated in the industrial and transport sectors, SENTHORIS now scales this innovation globally.
Let's catch up! 27–30 October 2025
Imagine: health assessed in 10 seconds - through the eyes. No samples. No pain. No delay.
SENTHORIS is an AI/ML-powered digital health platform redefining how the world detects an early neuro-metabolic risks, psychoactive effects and other risks through the pupil dynamic response.
Clinically grounded and validated in the industrial and transport sectors, SENTHORIS now scales this innovation globally.
Dynamic pupillometry is the quantitative measurement and analysis of the pupil’s response to light stimuli over time, capturing the kinetics of both constriction and dilation phases.
Dynamic pupillometry is clinically valuable for assessing autonomic nervous system function, detecting early neuro-ophthalmic or systemic disease (diabetic autonomic neuropathy, concussion), and monitoring neurological status in acute care settings.
In summary, dynamic pupillometry refers to the real-time, quantitative assessment of pupil reactivity to light, providing detailed metrics of pupillary function that reflect both parasympathetic and sympathetic integrity.
Dynamic pupillometry is clinically valuable for assessing autonomic nervous system function, detecting early neuro-ophthalmic or systemic disease (diabetic autonomic neuropathy, concussion), and monitoring neurological status in acute care settings.
In summary, dynamic pupillometry refers to the real-time, quantitative assessment of pupil reactivity to light, providing detailed metrics of pupillary function that reflect both parasympathetic and sympathetic integrity.
Health assessed in 10 seconds - through the eyes
No samples. No pain. No delay
No samples. No pain. No delay
VISION
VISION
At the Global Health Exhibition in Riyadh, 2025, SENTHORIS presented its AIML-based screening technology - an ecosystem that identifies metabolic disorders (early signs of diabetes) and psychoactive effects based on pupil response in less than 10 seconds using a camera.
Our mission: to build a future-ready healthcare system, enhance public safety, and drive innovation through data sovereignty and strategic partnerships.
Our aspiration: to build strategic partnerships for technology localization, investment and scaling.
Our mission: to build a future-ready healthcare system, enhance public safety, and drive innovation through data sovereignty and strategic partnerships.
Our aspiration: to build strategic partnerships for technology localization, investment and scaling.
What problems are we solving?
What problems are we solving?
DPLR at scale. Real-world engineering. Real customers. Real data.
Early Signs of Diabetes - our first priority
In 2024, the number of people with diabetes reached ~589 million, and by 2050 it is projected to grow to ~853 million (IDF). There is no simple way to detect early signs of diabetes before symptoms appear.
Our DPLR technology captures early autonomic nerve changes in Type II Diabetes - measurable shifts of 30–50% appear before clinical symptoms. These optical biomarkers enable non-invasive detection of early diabetic neuropathy, opening a new frontier in proactive, preventive diabetic care through the eyes.
Only 1 step remains to create a new standard for non-invasive screening of the next generation to help millions of people around the world. Early-warning digital health layer delivering predictive signals.
Our DPLR technology captures early autonomic nerve changes in Type II Diabetes - measurable shifts of 30–50% appear before clinical symptoms. These optical biomarkers enable non-invasive detection of early diabetic neuropathy, opening a new frontier in proactive, preventive diabetic care through the eyes.
Only 1 step remains to create a new standard for non-invasive screening of the next generation to help millions of people around the world. Early-warning digital health layer delivering predictive signals.
Neurological Risks
SENTHORIS analyzes micro-oscillations and irregularities of the pupil response to reveal early neuro-functional disorders.
Early signs of dementia, Parkinson’s disease, depression, and other neurodegenerative conditions: develops digital biomarkers of cognitive dysfunction.
Early signs of dementia, Parkinson’s disease, depression, and other neurodegenerative conditions: develops digital biomarkers of cognitive dysfunction.
Detection of Narcotic Influence or Toxic Poisoning
The pilot project in transport has been completed, and the first commercial deployment launched in the oil & gas sector (EU). We are focused on real-world implementation, followed by continuous adaptation and technological evolution.
Unique contribution to diabetes: working in three windows of opportunity
1: Presymptomatic screening
Who: Healthy individuals at risk (obesity, MetS, family history)
When: Glucose is NORMAL, but autonomic dysfunction is already present
Value: Diabetes prevention (lifestyle intervention)
When: Glucose is NORMAL, but autonomic dysfunction is already present
Value: Diabetes prevention (lifestyle intervention)
2: Early detection of prediabetes
Who: IGT/IFG (prediabetes: glucose 100-125 mg/dl)
When: Glucose is already elevated, but NOT YET diabetes
Value: Intervention before irreversible changes occur
When: Glucose is already elevated, but NOT YET diabetes
Value: Intervention before irreversible changes occur
3: Early detection of neuropathy in diabetes
Who: Patients diagnosed with diabetes WITHOUT retinopathy
When: Diabetes is confirmed, but complications are not yet present (or visible)
Value: Detection of neuropathy BEFORE irreversible damage occurs
When: Diabetes is confirmed, but complications are not yet present (or visible)
Value: Detection of neuropathy BEFORE irreversible damage occurs
How Does it Work?
The pupil is a direct mirror of the nervous system. Any change in light, emotion, or chemical state triggers a microscopic and precisely coordinated reaction — constriction or dilation — controlled by the brain’s autonomic centers.
Previously, such measurements were almost impossible: a doctor could only observe or roughly assess the reaction visually.
Our algorithms detect what the human eye cannot see — minimal deviations, hidden patterns, and dynamics at the level of thousandths of a second.
SENTHORIS uses this data to identify objective biomarkers related to neuro-autonomic, metabolic, or toxic processes.
Our algorithms detect what the human eye cannot see — minimal deviations, hidden patterns, and dynamics at the level of thousandths of a second.
SENTHORIS uses this data to identify objective biomarkers related to neuro-autonomic, metabolic, or toxic processes.
This is pure science — a clinically proven technology, engineering precision, and a mathematical model that transforms the smallest movements of the pupil into a reliable source of information about human health.
Accuracy Evolution
Accuracy Evolution
- Up to 98% accuracy and 100% specificity in controlled intoxication studies,
- 1,600+ subjects, 5000 + measurements
- AUC ≈ 0.93, 92–95% overall accuracy in real-world tests
Proof-of-concept related to diabetes
- AUC 0.69 - 0.71, sensitivity up to 81.6% and specificity up to 84.3%
- designed to reach ≥ 95% sensitivity,
- ≥ 95% specificity under formal medical-device validation.
Competitive Advantages
Our contribution to the national healthcare programme
for prevention medicine, digitalisation
and public safety
-
Non-invasive rapid test10-second testing without biomaterial — a combination of speed, non-invasiveness and reliable accuracy (≥ 90%) -
Next-generation pupillometryUse of validated data and AI/ML algorithms trained on thousands of reference reactions. Fully vertically integrated value chain – proprietary equipment for clinical research to end-to-end digital products. -
FlexibilityCompatible with 3 billion+ devices; deployable instantly via app, API, or SDK. -
Proven reaction of the pupilResearch (5,000+ tests) provides reliable correlation between pupil response and drug effects. Pilots and 1st commercial deployment in oil & gas provide practical verification and value. -
AI-second level analysisNot just automation, but "smart" forecasting, risk stratification, the possibility of early warning and the creation of an individual health profile. -
Edge-AI Privacy & SecurityReal-time local analysis without transmitting personal data — GDPR/HIPAA compliant. -
Partnership with a CRO leadersDevelopment of a protocol for international multicentre clinical trials for further scaling and certification of digital products as SaMD. -
Dual Product ModelUSMC — telemedicine modules (transport, manufacturing, oil and gas, public healthcare); SENTHORIS — software, mobile AI-powered platform (B2B, B2G - SaaS, API, SDK) -
Compliance and scaleFDA / SaMD pathways — designed for international certification, global scalability (the diabetes diagnostics market around $47B, and drug screening market could reach $20B by 2030)
Vertically Integrated Technology: from optics to AI/ML
SENTHORIS is being built as a vertically integrated platform that combines custom hardware, dedicated software, and advanced AI/ML analytics into a single pipeline from research to real-world deployment.
Our current development starts with the proprietary research pupillometer - a custom-designed optical instrument, produced specifically for data collection in clinical and field studies.
Our current development starts with the proprietary research pupillometer - a custom-designed optical instrument, produced specifically for data collection in clinical and field studies.
It operates together with dedicated control software that standardizes light stimulation, ensures precise timing of the pupil response, and securely transmits high-fidelity eye signal data to our research environment. This stack forms the foundation for training and validating our AI/ML models within formal clinical protocols.
In the next phase, the same data architecture will support product-grade solutions - mobile applications, enterprise interfaces, and SDK/API integrations - so that models validated in trials can be deployed into real screening workflows with minimal adaptation.
By controlling the full stack from signal acquisition to analytics and interfaces, SENTHORIS maintains robust quality, data integrity, and regulatory-ready traceability, creating a trusted end-to-end ecosystem for next-generation, non-invasive digital diagnostics.
In the next phase, the same data architecture will support product-grade solutions - mobile applications, enterprise interfaces, and SDK/API integrations - so that models validated in trials can be deployed into real screening workflows with minimal adaptation.
By controlling the full stack from signal acquisition to analytics and interfaces, SENTHORIS maintains robust quality, data integrity, and regulatory-ready traceability, creating a trusted end-to-end ecosystem for next-generation, non-invasive digital diagnostics.
EYE + CAMERA + AI/ML =
Sensing Technology
The eyes as a universal and reliable biosensor
Sensing Technology
The eyes as a universal and reliable biosensor
SENTHORIS is a vertically integrated diagnostic ecosystem that transforms the pupil into a universal gateway for health and safety intelligence.
From proprietary pupillometers and specialized software for clinical research, to AI-driven analytics, mobile apps, and enterprise integrations. Every layer is engineered and controlled within one continuum.
The platform detects neuro-autonomic, toxicological, and metabolic (early signs of diabetes) changes in seconds, without biosamples or discomfort.
It brings objective, real-time screening to workplaces, healthcare systems, and public infrastructure, creating a new layer of preventive intelligence for industrial environments, transport networks, and the cities of the future.
SENTHORIS serves three categories:
More than a device or an app, SENTHORIS is a living system - a connected layer of care, vigilance, and foresight embedded in the cognitive ecosystems of tomorrow.
From proprietary pupillometers and specialized software for clinical research, to AI-driven analytics, mobile apps, and enterprise integrations. Every layer is engineered and controlled within one continuum.
The platform detects neuro-autonomic, toxicological, and metabolic (early signs of diabetes) changes in seconds, without biosamples or discomfort.
It brings objective, real-time screening to workplaces, healthcare systems, and public infrastructure, creating a new layer of preventive intelligence for industrial environments, transport networks, and the cities of the future.
SENTHORIS serves three categories:
- Individuals — self-checks and early risk awareness.
- Enterprises — workforce health and operational safety.
- Governments & Smart Cities — digital health monitoring at population scale.
More than a device or an app, SENTHORIS is a living system - a connected layer of care, vigilance, and foresight embedded in the cognitive ecosystems of tomorrow.
Benefits & Impact
We are pragmatic engineers — and parents.
We work with the conviction that technology can make life healthier and longer, helping nations prevent disease rather than react to it.
We work with the conviction that technology can make life healthier and longer, helping nations prevent disease rather than react to it.
-
Early metabolic risk detection
Supports national prevention programs, reduces incident rates, and builds an anonymized biometric data base for early public-health insights. -
Unified platform for prevention
Covers three domains: metabolic, psychoactive, neurological - through one clinical pathway and AI/ML framework ready for KSA-localization and scaling. -
From field validation to clinical readiness
Proven in transport and industrial pilots; now entering global multi-center trials to certify DPLR biomarkers for diabetes and other health risks. -
Health data for a stronger nation
Supports flagship and national strategic programs in healthcare by reducing preventable diseases, strengthening public health, and creating a sovereign data repository for future innovation.
It's not a product
It's an ecosystem
It's an ecosystem
Foundation (2022)
Engineering and data groundwork - transforming years of clinical insight into a scalable digital architecture. Creation of first functional prototypes and AI/ML-ready data structure.
Industrial Pilots (2023-2025)
USMC modules deployed in transport.
1st Commercial Deployment & Platform Evolution (2025)
Launch of the first commercial project in oil&gas, and transition to SENTHORIS AI-based software platform. Integration of validated datasets and ML architecture.
Clinical Research Preparation (2025)
Pre-design of the international clinical protocol - defining scope, endpoints, and data strategy.
Technology Presentation – Riyadh (GHE 2025)
1st official presentation of SENTHORIS at the Global Health Exhibition, Saudi Arabia. Searching for strategic partners and project funding to create a new standard for non-invasive digital screening as a contribution to preventive medicine.
Clinical Validation (2026 - 2027)
Execution of large-scale multicountry clinical studies for certification (US, APAC). Reaching regulatory readiness FDA SaMD as a final target.
Global Rollout
Launch of certified SENTHORIS AI-based platform and ecosystem worldwide - across healthcare, industry, and preventive diagnostics.
MEET OUR TEAM
-
Denis Zalynskiy
Engineering Heart
of the company, EU
A leading researcher and technology innovator with extensive experience in project leadership, manufacturing facility development, and product improvement. Dedicated to driving innovation through a scientific approach.
-
Maxim Zagryadskiy
Head of
IT Development
An experienced IT leader with 8+ years in NET/C# development, system integration, and backend architecture. Skilled in building high-load services and digital platforms for industrial and medical sectors. Focused on turning complex technical challenges into reliable solutions that support business growth and digital transformation.
-
Artem Karavatyi
Strategy, operations, implementation management, EU
A seasoned international advisor guiding top-level executives across diverse enterprises. Possesses a strong strategic vision combined with a pragmatic approach to problem-solving, from initial concept development through successful implementation.
“
We see what the eyes cannot hide. Detection of early signs of diabetes, neurological disorders, and other health risks. Our goal is to make the eyes an accessible, reliable, and universal tool for rapid, non-invasive health screening with a transition to the SaMD.
Press Release / 29.10.2025
SENTHORIS announces collaboration with Thermo Fisher Scientific, Riyadh, KSA
SENTHORIS announces collaboration with Thermo Fisher Scientific, Riyadh, KSA
On the sidelines of the Global Health Exhibition 2025, the SENTHORIS project and Thermo Fisher Scientific’s PPD™ Clinical Research business signed a Commitment Letter establishing a strategic intent to collaborate in the field of digital diagnostics and clinical research.
The intended collaboration is aimed at joint development and localization of artificial intelligence technologies for non-invasive medical screening — a contribution to the implementation of Vision 2030 objectives for strengthening the innovative economy and preventive healthcare of the Kingdom of Saudi Arabia.
The Letter reflects the common aspiration of the parties to combine scientific and technological expertise to create a new standard for digital health screening.
_______
The founders of SENTHORIS view this step as a basis for further dialogue with investors, academic institutions and health organizations, whose direct involvement will be crucial for the long-term development of the project. The SENTHORIS project welcomes cooperation with national stakeholders to define the next stages of the program in alignment with the strategic priorities in health innovation and AI transformation.
The intended collaboration is aimed at joint development and localization of artificial intelligence technologies for non-invasive medical screening — a contribution to the implementation of Vision 2030 objectives for strengthening the innovative economy and preventive healthcare of the Kingdom of Saudi Arabia.
The Letter reflects the common aspiration of the parties to combine scientific and technological expertise to create a new standard for digital health screening.
_______
The founders of SENTHORIS view this step as a basis for further dialogue with investors, academic institutions and health organizations, whose direct involvement will be crucial for the long-term development of the project. The SENTHORIS project welcomes cooperation with national stakeholders to define the next stages of the program in alignment with the strategic priorities in health innovation and AI transformation.
Go to WhatsApp live chat with co-founder (Artem Karavatyi)
+359-886-899-089 WhatsApp
a.karavatyi@mededteh.com
Let's explore how we can contribute
to the healthcare ecosystems!
© 2013-2025, EVERTON LTD and
3D Happy LTD group, Bulgaria
All Rights Reserved
3D Happy LTD group, Bulgaria
All Rights Reserved